Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists
作者:Roberto Butera、Marta Ważyńska、Katarzyna Magiera-Mularz、Jacek Plewka、Bogdan Musielak、Ewa Surmiak、Dominik Sala、Radoslaw Kitel、Marco de Bruyn、Hans W. Nijman、Philip H. Elsinga、Tad A. Holak、Alexander Dömling
DOI:10.1021/acsmedchemlett.1c00033
日期:2021.5.13
work, we designed a new scaffold based on our previously solved high-resolution structures of low-molecular-weight inhibitors bound to PD-L1. A small compound library was synthesized using the Groebke–Blackburn–Bienaymé multicomponent reaction (GBB-3CR), resulting in the structure–activity relationship of imidazo[1,2-a]pyridine-based inhibitors. These inhibitors were tested for their biological activity
PD-1 / PD-L1轴已被证明是使用几种已批准的抗体进行癌症免疫检查点治疗的高效靶标。同样,基于联苯核心的小分子可以拮抗PD-1 / PD-L1,导致体外形成PD-L1二聚体。但是,由于我们尚未完全了解他们的行动方式,他们的发展仍然充满挑战。在这项工作中,我们基于先前解决的与PD-L1结合的低分子量抑制剂的高分辨率结构,设计了一种新的支架。小化合物文库使用Groebke-布莱克- Bienaymé多组分反应(GBB-3CR)中合成,从而导致咪唑的结构-活性关系[1,2一基于]吡啶的抑制剂。使用各种生物物理测定法测试了这些抑制剂的生物活性,从而给出了具有低微摩尔PD-L1亲和力的有效候选物。所获得的PD-L1共晶体结构揭示了与PD-L1的结合。我们的结果为有趣的生物活性支架打开了大门,该支架可能会导致新型的PD-L1拮抗剂。